p53 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry

Journal of Biological Sciences

Volumn 8, Issue 2, 2008, Pages 380-385

  Kaabinejadian, S ^a,b   Fouladdel, Sh ^a   Ramezani, M ^b   Azizi, Ebrahim ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adriamycin; Breast cancer; Immunocytochemistry; p53; RT PCR

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; MESSENGER RNA; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRAIN DIFFERENCE;

EID: 52349083889     PISSN: 17273048     EISSN: 18125719     Source Type: Journal    
DOI: 10.3923/jbs.2008.380.385     Document Type: Article

References (22)

1. Anelli, A., R.R. Brentani, A.P. Gadelha, A. Amorim de Albuquerque and F. Soares, 2003. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxombicin in stage IIIB breast cancer. Ann. Oncol., 14 (3): 428-432.
2. Angeloni, S.V., M.B. Martin, P. Garcia-Morales, M.D. Castro-Galache, J.A. Ferragut and M. Saceda, 2004. Regulation of estrogen receptor-α expression by the tumor suppressor gene p53 in MCF-7 cells. J. Endocrinol., 180 (3): 497-504.
3. Borresen-Dale, A.L., 2003. TP53 and Breast cancer. Hum. Mutat., 21 (3): 292-300.
4. Carmichael, J., W.G. DeGraff, A.F. Gazdar, I.D. Minna and J.B. Mitchell, 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res., 47 (4): 936-942.
5. Cetin-Atalay, R. and M. Ozturk, 2000. p53 mutations as fingerprints of environmental carcinogens. Pure Applied Chem., 72 (6): 995-999.
6. Chomczynski, P. and N. Sacchi, 1987. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Anal. Biochem., 102 (1): 156-159.
7. Feki, A. and I. Irminger-Finger, 2004. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol., 52 (2): 103-116.
8. Gewirtz, D.A., 1999. A critical evaluation of the mechanisms of action proposed for the antitmnor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57 (7): 727-741.
9. Hayashi, S.I., H. Eguchi, K. Tanimoto, T. Yoshida, Y. Omoto, A. Inoue, N. Yosida and Y. Yamaguchi, 2003. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr. Relat. Cancer, 10 (2): 193-202.
10. Jemal, A., T. Murray, A. Samuels, A. Ghafoor, E. Ward and M.J. Thun, 2003. Cancer statistics. CA Cancer. J. Clin., 53 (1): 5-26.
11. Lacroix, M., R.A. Toillon and G. Leclercq, 2006. p53 and breast cancer, an update. Endocr. Relat. Cancer, 13 (2): 293-325.
12. Liu, G., J.A. Schwartz and S.C. Brooks, 2000. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res., 60 (7): 1810-1814.
13. Liu, W., S.D. Konduri, S. Bansal, B.K. Nayak, S.A. Rajasekaran, S.M. Karuppayil, A.K. Rajasekaran and G.M. Das, 2006. Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function. J. Biol. Chem., 281 (15): 9837-9840.
14. Meek, D.W., 2004. The p53 response to DNA damage. DNA Repair, 3 (8-9): 1049-1056.
15. Michalak, E., A. Villunger, M. Erlacher and A. Strasser, 2005. Death squads enlisted by the tumour suppressor p53. Biochem. Biophys. Res. Commun., 331 (3): 786-798.
16. Miller, L.D., J. Smeds, J. George, V.B. Vega, L. Vergara, A. Ploner, Y. Pawitan, P. Hall, S. Klaar, E.T. Liu and J. Bergh, 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects and patient survival. PNAS., 102 (38): 13550-13555.
17. Montero, S., C. Guzman, C. Vargas, C. Ballestin, H. Cortes-Funes and R. Colomer, 2001. Prognostic value of cytosolic p53 protein in breast cancer. Tumor Biol., 22 (5): 337-344.
18. Olivier, M., R. Eeles, M. Hollstein, M.A. Khan, C.C. Harris and P. Hainaut, 2002. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat., 19 (6): 607-614.
19. Putti, T.C., D.M. Abd El-Rehim, E.A. Rakha, E. Claire Paish, A.H.S. Lee, S.E. Pinder and I.O. Ellis, 2005. Estrogen receptor-negative breast carcinomas: A review of morphology and immunophenotypical analysis. Mod. Pathol., 18 (1): 26-35.
20. Shu, K.X., B. Li and L.X. Wu, 2007. The p53 network: p53 and its downstream genes. Colloids Surf. B: Biointerfaces, 55 (1): 10-18.
21. Soussi, T. and C. Beroud, 2001. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat. Rev. Cancer, 1 (3): 233-240.
22. Vousden, K.H. and X. Lu, 2002. Live or let die: The cell's response to p53. Nat. Rev. Cancer, 2 (8): 594-604.